http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
최남미(Choe, Nammi),임종빈(Im, Jongbin),정서영(Chung, Soyoung),박정호(Park, Jung Ho),김영규(Kim, Youngkyu),정승미(Chung, Seungmi) 한국항공우주연구원 2013 항공우주산업기술동향 Vol.11 No.1
2008년 미국 발 경제위기에도 불구하고 세계 우주 예산은 계속 상승세를 보이며 2012년 729억 달러로 역대 최대치를 기록했다. 미국과 유럽의 우주 분야 투자는 감소하거나 성장 둔화세를 보이고 있으나 우주 분야에 새롭게 진입한 국가들의 증가와 러시아, 중국과 남미와 중동의 국가들이 공격적인 투자를 하면서 우주 예산의 증가를 이끌었다. 2012년에 세계 여러 국가들은 앞으로의 우주개발 계획과 정책을 발표하였다. 러시아는 2020년까지의 우주개발 계획과 2030년까지의 우주활동의 방향을 담은 정책을 각각 발표하며 우주분야에 대한 투자를 강조했다. 유럽 또한 ‘경쟁력 지속을 위한 새로운 우주산업 정책’을 발표했으며, 일본과 중국, 인도 등도 각각 앞으로의 로드맵과 개발 계획을 발표하여 앞으로의 활발한 우주 활동을 예상하게 했다. 우리나라는 2012년과 2013년 상반기에 걸쳐 다목적 실용위성 3호와 나로호 3차 발사를 성공함으로 우리나라의 우주개발에 중요한 이정표를 세웠다. 또한 새로 출범한 박근혜 정부에서 우주 분야를 주목하고 있다. 2012년 예산은 전년도에 비해 다소 감소하였으나 2013년 들어 한국형 발사체 개발 사업이 본격화 되면서 우주예산이 역대 최고치를 기록했다. 본 논문에서는 세계 각국의 우주개발 투자와 연구 개발 활동을 살펴보았으며, 우리나라와의 비교를 통해 우리나라 우주 정책의 현 주소를 가늠해보았다. The world governments" investments on space program have continuously increased and reached a historical peak of $72.9 billion in 2012 despite of the financial crisis of 2008 from the U. S. The investments of the U. S. and European countries reduced or maintained their investment on space program, however, the new starters of space program in Middle Asia and Latin America, Russia, and China show enormous growth of space budget. The Space Powers announced their plans of space programs and policies in 2012. Russia showed the will of space activities through the new plan of space development until 2020 and policies for space activities until 2030. Europe, China, Japan, and India also showed various future space programs through new plans and roadmaps of their space programs. Korea succeeded the launches of KOMPSAT-3 and KSLV-1 in 2012 and early 2013. These successes are the milestones of Koreans space history. And the new administration of President Geun-hye Park considers the important policy issues and started strong support on space programs. Korean space budget in 2013 is expected to reach the peak with KSLV-2 project. In this paper, the investment of world governmental space program and research activities were presented and compared with Korean space activities and policies. Through these, current status of Korean space policies was reviewed.
Resveratrol Induces Glioma Cell Apoptosis through Activation of Tristetraprolin
Ryu, Jinhyun,Yoon, Nal Ae,Seong, Hyemin,Jeong, Joo Yeon,Kang, Seokmin,Park, Nammi,Choi, Jungil,Lee, Dong Hoon,Roh, Gu Seob,Kim, Hyun Joon,Cho, Gyeong Jae,Choi, Wan Sung,Park, Jae-Yong,Park, Jeong Woo Korean Society for Molecular and Cellular Biology 2015 Molecules and cells Vol.38 No.11
Tristetraprolin (TTP) is an AU-rich elements (AREs)-binding protein, which regulates the decay of ARE-scontaining mRNAs such as proto-oncogenes, anti-apoptotic genes and immune regulatory genes. Despite the low expression of TTP in various human cancers, the mechanism involving suppressed expression of TTP is not fully understood. Here, we demonstrate that Resveratrol (3,5,4'-trihydroxystilbene, Res), a naturally occurring compound, induces glioma cell apoptosis through activation of tristetraprolin (TTP). Res increased TTP expression in U87MG human glioma cells. Res-induced TTP destabilized the urokinase plasminogen activator and urokinase plasminogen activator receptor mRNAs by binding to the ARE regions containing the 3' untranslated regions of their mRNAs. Furthermore, TTP induced by Res suppressed cell growth and induced apoptosis in the human glioma cells. Because of its regulation of TTP expression, these findings suggest that the bioactive dietary compound Res can be used as a novel anti-cancer agent for the treatment of human malignant gliomas.
Ryu, Jinhyun,Yoon, Nal Ae,Lee, Yeon Kyung,Jeong, Joo Yeon,Kang, Seokmin,Seong, Hyemin,Choi, Jungil,Park, Nammi,Kim, Nayoung,Cho, Wha Ja,Paek, Sun Ha,Cho, Gyeong Jae,Choi, Wan Sung,Park, Jae-Yong,Park, Korean Society for Molecular and Cellular Biology 2015 Molecules and cells Vol.38 No.2
Urokinase plasminogen activator (uPA) and urokinase plasminogen activator receptor (uPAR) play a major role in the infiltrative growth of glioblastoma. Downregulatoion of the uPA and uPAR has been reported to inhibit the growth glioblastoma. Here, we demonstrate that tristetraprolin (TTP) inhibits the growth of U87MG human glioma cells through downregulation of uPA and uPAR. Our results show that expression level of TTP is inversely correlated with those of uPA and uPAR in human glioma cells and tissues. TTP binds to the AU-rich elements within the 3' untranslated regions of uPA and uPAR and overexpression of TTP decreased the expression of uPA and uPAR through enhancing the degradation of their mRNAs. In addition, overexpression of TTP inhibited the growth and invasion of U87MG cells. Our findings implicate that TTP can be used as a promising therapeutic target to treat human glioma.
박지윤,Nammi Park,Sangjin Han,Lee You-Bin,김규리,Jin Sang-Man,이우제,김재현 대한당뇨병학회 2022 Diabetes and Metabolism Journal Vol.46 No.6
This study evaluated the safety and efficacy of tubeless patch pump called EOPatch in patients with well-controlled type 1 diabetes mellitus (T1DM). This 4-week, two-center, open-label, single-arm study enrolled 10 adult patients diagnosed with T1DM with glycosylated hemoglobin less than 7.5%. The co-primary end points were patch pump usage time for one attachment and number of serious adverse events related to the patch pump. The secondary end points were total amount of insulin injected per patch and changes in glycemic parameters including continuous glucose monitoring data compared to those at study entry. The median usage time per patch was 84.00 hours (interquartile range, 64.50 to 92.50). Serious adverse events did not occur during the trial. Four weeks later, time in range 70 to 180 mg/dL was significantly improved (70.71%±17.14 % vs. 82.96%±9.14%, <i>P</i>=0.01). The times spent below range (<54 mg/dL) and above range (>180 mg/dL) also improved (All <i>P</i><0.05). Four-week treatment with a tubeless patch pump was safe and led to clinical improvement in glycemic control.
HS-1793 protects C2C12 cells from oxidative stress via mitochondrial function regulation
MARQUEZ JUBERT,Park Nammi,Maria Victoria Faith Garcia,Kim Hyoung Kyu,Han Jin 대한독성 유전단백체 학회 2020 Molecular & cellular toxicology Vol.16 No.4
Background HS1793, a novel analogue of resveratrol, was previously determined to be more potent at lower dosages by improving mitochondrial function and increased mitochondrial biogenesis-related proteins. In this study, we focused on targeting the mitochondria to address muscle wasting with HS-1793. Method Dosage screening was performed by evaluating for cytotoxicity and cell proliferation. Mitochondrial mass, mitochondrial membrane potential (Δψm), reactive oxygen species (ROS) level, and mitochondria biogenesis-regulated genes and proteins were analyzed to determine the efects on mitochondrial biogenesis. Results HS-1793 reduced ROS generation, but treatment did not interfere with cellular viability at low dosages. HS-1793 also regulated mitochondrial function by increasing cellular and mitochondrial ATP synthesis function, stabilizing Δψm and decreasing ROS. More importantly, these dysfunction in these parameters were ameliorated by HS-1793 in a simulated oxidative stress model with tBHP. We also observed increase in mitochondrial mass and upregulation in vital mitochondrial biogenesis-related gene PGC1-α as a response to HS-1793 treatment. Moreover, phosphorylation of AKT and mTOR proteins, which are considered as regulators of skeletal muscle function were also increased during the treatment. Finally, HS-1793 also demonstrated protective efects against cisplatin-induced skeletal muscle cell injury by increasing expression of mitochondrial biogenesis-relate markers. Conclusion Taken altogether, it shows the viability of HS-1793 as a compound that can restore mitochondrial function and render protection in skeletal muscle cells, especially during high oxidative stress levels.
CHOI, HYE YOUNG,PARK, NAMMI,NA, JAE BOEM,KO, EUN SOOK,PARK, JAE-YONG,YOO, JAE CHEAL Spandidos Publications 2016 ONCOLOGY REPORTS Vol.35 No.2
<P>Copine3, a known calcium-dependent membrane binding protein, contains two tandem C2 domains and an A domain. This protein has been shown to interact with receptor tyrosine kinase 2 (ErbB2), but little is known concerning the physiological function of Copine3. To better understand its cellular function, we carried out a yeast two-hybrid screen to find Copine3 binding partners. Among the identified proteins, Jun activation domain-binding protein 1 (Jab1) appears to directly interact with Copine3. This physical interaction between Copine3 and Jab1 as well as the specific binding regions of both proteins were confirmed in vitro and in vivo. Our results also demonstrate that binding of Copine3 to ErbB2 is increased when Jab1 is overexpressed in SKBr3 breast cancer cells. Furthermore, two ErbB2 downstream signaling proteins [phosphatidylinositol 3 (PI3) kinase and protein kinase B (AKT)] were also activated by Jab1 overexpression in these cells. These data suggest that binding of Copine3 and Jab1 regulates, at least to some extent, the ErbB2 signaling pathway. Moreover, overexpression of both Copine3 and Jab1 in SKBr3 cells effectively increased cellular migration. Collectively, our findings indicating that Jab1 enhances the ErbB2 binding ability of Copine3, further activating the ErbB2 signaling pathways involved in breast cancer cell pathogenesis.</P>